Cresud reports FQ1 results (CRESY:NASDAQ)

Cresud reported FQ1 2027 net income of ARS 26.331 billion, down from ARS 146.866 billion in the same quarter of 2026. Adjusted EBITDA rose 66.4% to ARS 130.401 billion year-over-year, according to the company.

Original reporting
Published Nov 10, 2026, 3:54 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 10, 2026, 3:58 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Cresud reports FQ1 results (CRESY:NASDAQ) — source image
Decision brief

The 30-second read

$CRESYBearishMed
01

Why it matters

The sharp profit decline is likely to trigger a sell‑off, though the EBITDA boost may soften the move.

02

Market read

First‑report earnings release with material profit miss; relevant for traders holding or considering CRESY.

03

What to watch

Currency fluctuations and one‑off items may have driven the profit drop.

Relevance 7/10Novelty 8/10Timing: post‑market today

Background

Cresud is an Argentine agribusiness company listed on NASDAQ under CRESY.

Company-level read

Ticker impact

$CRESYBearishMedium confidence
Context

Cresud reported Q1 net income of ARS 26.3bn, down sharply from ARS 146.9bn a year earlier, while adjusted EBITDA rose 66% YoY.

Expected impact

likely downward pressure as investors digest the profit decline

Evidence & confidence

Profit fell dramatically, a key profitability metric, which typically triggers sell‑offs even if cash flow improves.

Market effects

Highlights volatility in Argentine agribusiness sector earnings.

May pressure other Latin‑American listed agribusiness stocks.

Limited; primarily relevant to investors with exposure to emerging‑market equities.

Counterpoint

EBITDA surge could signal operational improvements that may support a rebound.

Key entities

  • Cresud

    Argentine agribusiness firm listed on NASDAQ.

Related articles

$CRESYMed

CRESUD INC (CRESY): Financial results for Q1 2027

CRESUD INC (CRESY) furnished an SEC Form 6-K — earnings release. Yes o No x CRESUD S.A.C.I.F. and A. (THE “COMPANY”) REPORT ON FORM 6-K Attached is the English translation of the letter filed with the Comision Nacional de Valores and Bolsa de Comercio de Buenos Aires on November 9, 2026. By letter dated November 9, 2026, the company reported t

$CRESYMed

CRESUD INC (CRESY): Financial results for FY2026

CRESUD INC (CRESY) furnished an SEC Form 6-K — earnings release. Yes o No x CRESUD S.A.C.I.F. and A. (THE “COMPANY”) REPORT ON FORM 6-K Attached is the English translation of the letter filed with the Comision Nacional de Valores and Bolsas y Mercados Argentinos S.A. on September 7, 2026. By letter dated September 7, 2026, the company reported

$DDOGHighAI 9/10

“Missing Forest-for-the-Trees”: Datadog Sinks 17% in a Week as Its Biggest AI Customer Cuts Back

Datadog (DDOG) stock fell 17% in a week after reporting 35% Q3 revenue growth to $1.2B but guiding Q4 revenue to $1.19-1.2B, roughly flat. The decline was driven by its largest AI customer reducing usage, though growth outside this customer is accelerating. Cloudflare (NET) reported strong Q3 results and a rising Q4 outlook, suggesting the slowdown may be isolated. Datadog trades at 60x forward earnings, below its usual multiple.

$NOVTHighAI 8/10

Novanta (NOVT) Q3 2026 Earnings Call Transcript

Novanta (NOVT) reported Q3 2026 revenue of $305M, up 23%, with organic growth of 10%. Adjusted EBITDA rose 38% to $80M, and adjusted EPS increased 21% to $1.05. The company acquired Riverpoint Medical, expanding its medical end markets to 53% of revenue. Customer bookings grew 29%, and backlog reached $543M. Operating cash flow tripled year-over-year to $156M. Novanta expects full-year 2027 gross margin expansion and strong earnings growth, driven by new products and acquisitions.

$AXONMed

Axon Sinks 27% in a Week to a New 52-Week Low. Is the Selling Overdone?

Axon shares dropped 27% in a week to a 52-week low after missing Q3 revenue estimates and lowering its 2026 outlook due to delayed federal Dedrone deployments. The company now expects $350M-$400M in free cash flow by 2026, down from $450M, and needs $450M in Q4 to meet targets. Competitors Motorola Solutions and Tyler Technologies reported strong demand. Analysts reduced 2027 EPS estimates to $9.55 from $10.51.